Experts from Wiley discuss a strategy-driven approach to Medical Education, powered by timely, credible information delivered in multiple formats.
This series of the Elevate Podcast illuminates how AI and Generative AI seem to be a part of every webinar, conference, and conversation these days. This podcast will explore three proof-of-concept (POC) use cases from recent work in the field of Medical Information.
Medical Affairs is uniquely positioned as the only department capable of impacting the Enterprise Commercialization Process (ECP) at every stage, from the initial product concept through the entire commercialization effort.
This article explores key questions on how Medical Affairs teams manage patient engagement across different-sized companies who have variations in focus, resources, and scale.
This article based on the Oct 3, 2024 Insights FAWG Forum explores the potential for artificial intelligence (AI) to transform Medical Affairs, focusing on medical insights.
Experts from Pfizer and Veeva explore a recent Veeva Pulse Report showing that targeted scientific outreach is associated with 40% faster treatment adoption.
We’ve developed real-time software that MA HQ and MSLs are already using daily to improve their physician insights, tailor field deployment and education, and track impact at the national, local, and individual physician level.
In this podcast, experts explore the many challenges associated with the operationalization of global Integrated Evidence Generation Planning (IEGP) at local levels.
What makes a publication interesting or impactful? Is it number of citations? Sentiment among important stakeholders? Relevance to the largest patient population? Popular news attention? The answer depends on your strategy. Here we speak with experts from Altmetric about 10 publications that are impactful for different reasons.
The Medical Affairs Professional Society (MAPS) is pleased to share our 2024 Digital, Advanced Analytics and Artificial Intelligence (AI) in Medical Affairs report. This report is based on findings from 32 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors, and reflects broad leadership thinking about the current and future states of Medical Affairs (MA) AI capability and challenges.
Survey design and analysis: Boston Consulting Group led the preparation, execution and analyses of the GenAI survey and moderated the Ambassador GenAI and Advanced Analytics workshop during the MAPS conference on March 24th, 2024.
Survey respondents: 34 representatives from 32 companies responded to our survey.
Participating companies: Thank you to participants from 3M, Abbott, AbbVie, Amgen, Astellas, AstraZeneca, Baxter, Bayer, bioMérieux, BioNTech, BMS, Eisai, Lilly, Gilead, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Mallinckrodt, Merck & Co, Mundipharma, Novartis, Otsuka, Regeneron, Sanofi, Sumitomo Pharma, Takeda, Teva, UCB, Varian, Vertex, and Viatris for your valuable feedback and insights.
The opinions expressed here are those of members of the MAPS Ambassador Alliance and do not necessarily represent the perspectives of their respective companies.